Unknown

Dataset Information

0

Advances in anti-BRAF therapies for lung cancer.


ABSTRACT: Non-small cell lung cancer (NSCLC) is one of the most frequent causes of mortality in the western world. v-raf murine sarcoma viral oncogene homolog B (BRAF) is a member of the Raf kinase family and plays a critical role in cellular growth, proliferation, and differentiation through the mitogen-activated protein kinase pathway. The incidence of BRAF mutations in NSCLC is low, accounting for 0-3% of all cases of lung cancer. Given the results obtained in metastatic melanoma, several studies have reported the efficacy of anti-BRAF therapies in NSCLC treatment. In this review, we describe changes in the landscape of BRAF-mutated lung cancer treatment and analyze insights from major clinical trials in the context of future therapeutic prospects.

SUBMITTER: Roviello G 

PROVIDER: S-EPMC8068629 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2014-12-30 | E-MTAB-2607 | biostudies-arrayexpress
| S-EPMC8280599 | biostudies-literature
| S-EPMC9556333 | biostudies-literature
| S-EPMC10175743 | biostudies-literature
| S-EPMC9895369 | biostudies-literature
| S-EPMC9721395 | biostudies-literature
| S-EPMC10493868 | biostudies-literature
| S-EPMC5138135 | biostudies-literature
| S-EPMC8417143 | biostudies-literature
| S-EPMC5233881 | biostudies-other